Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

AstraZeneca
Cerilliant
Fuji
Cantor Fitzgerald
US Department of Justice
Mallinckrodt
Fish and Richardson
Healthtrust
Cipla

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 019991

« Back to Dashboard

NDA 019991 describes NOVOLIN 70/30, which is a drug marketed by Novo Nordisk Inc and is included in two NDAs. It is available from three suppliers. Additional details are available on the NOVOLIN 70/30 profile page.

The generic ingredient in NOVOLIN 70/30 is insulin recombinant human; insulin susp isophane recombinant human. There are thirty-nine drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the insulin recombinant human; insulin susp isophane recombinant human profile page.
Summary for 019991
Tradename:NOVOLIN 70/30
Applicant:Novo Nordisk Inc
Ingredient:insulin recombinant human; insulin susp isophane recombinant human
Patents:0
Formulation / Manufacturing:see details
Suppliers and Packaging for NDA: 019991
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
NOVOLIN 70/30 insulin recombinant human; insulin susp isophane recombinant human INJECTABLE;INJECTION 019991 NDA Novo Nordisk 0169-1837 N 0169-1837-02
NOVOLIN 70/30 insulin recombinant human; insulin susp isophane recombinant human INJECTABLE;INJECTION 019991 NDA Novo Nordisk 0169-1837 N 0169-1837-11

Profile for product number 001

Active Rx/OTC/Discontinued:OTCDosage:INJECTABLE;INJECTIONStrength30 UNITS/ML;70 UNITS/ML
Approval Date:Jun 25, 1991TE:RLD:Yes

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Argus Health
Express Scripts
Dow
Merck
Queensland Health
US Department of Justice
Cerilliant
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.